Related Experiment Video

Updated: Aug 7, 2026

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration
11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

Protein kinase C-beta as a therapeutic target in breast cancer

George W Sledge1, Yesim Gökmen-Polar

  • 1Departments of Medicine and Pathology, Indiana University Cancer Center, Indianapolis, IN 46220, USA. gsledge@iupui.edu

Seminars in Oncology
|June 27, 2006
PubMed

Insights

Targeting protein kinase C (PKC)-beta shows promise for breast cancer treatment. PKC-beta inhibition effectively suppresses tumor growth and angiogenesis, supporting its clinical investigation.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Protein kinase C (PKC)-beta, particularly the PKC-beta II variant, is implicated in breast cancer tumorigenesis.
  • PKC-beta mediates vascular endothelial growth factor-induced endothelial cell proliferation, a key driver of tumor angiogenesis and growth.
  • PKC-beta signaling pathways are increasingly recognized as critical targets in cancer therapy.

Purpose of the Study:

  • To review the preclinical and clinical rationale for targeting PKC-beta in breast cancer.
  • To highlight the role of PKC-beta in tumor growth and angiogenesis.
  • To discuss the potential of PKC-beta inhibitors in breast cancer treatment.

Main Methods:

  • Review of preclinical studies on PKC-beta function in breast cancer models.
  • Analysis of clinical trial data for PKC-beta inhibitors like enzastaurin and ruboxistaurin.
  • Examination of the role of vascular endothelial growth factor (VEGF) in mediating PKC-beta effects.

Main Results:

  • PKC-beta II is a significant factor in tumorigenesis.
  • PKC-beta is a key mediator of VEGF-induced endothelial cell proliferation and tumor angiogenesis.
  • PKC-beta-selective inhibitors, such as enzastaurin, have demonstrated efficacy in suppressing tumor growth and angiogenesis in preclinical models.
  • Enzastaurin has shown promising results in Phase II clinical trials for other cancers.

Conclusions:

  • PKC-beta is a validated therapeutic target for breast cancer.
  • Inhibitors of PKC-beta represent a promising strategy for combination therapy in breast cancer.
  • Further clinical investigation of PKC-beta inhibitors in breast cancer is warranted.

More Related Videos

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach11:11

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach

Published on: February 21, 2019

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include: